Akebia Therapeutics (AKBA) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results
November 12, 2019 7:57 AM ESTFunding expected to extend Companys cash runway into 2021, well past its expected topline data readouts for global Phase 3 studies for vadadustat; MTPCs positive Phase 3 data show vadadustats effect on hemoglobin was sustained through to 52 weeks; Auryxia ® (ferric citrate) revenue increases to $30.0 million for Q3FY19, up 13% from Q3FY18; and, Company hosts call to discuss financial results and recent business highlights
CAMBRIDGE, Mass.--(BUSINESS... More
